Fluxion Biosciences

NIH grant funds development of system critical to stem cell and siRNA research

January 10, 2006, San Francisco, CA - Fluxion Biosciences, a leading developer of microfluidic systems for cellular assays in life sciences research and drug discovery, today announced that it has received a National Institutes of Health grant for the development of a single-cell electroporation system. The grant leverages the microfluidics technologies that Fluxion is developing for a wide range of cellular assays.

The NIH awarded this grant to further the development of Fluxion's intracellular delivery platform. The Company has developed a bencthop workstation capable of selecting and trapping individual cells which can then be loaded with biological reagents. Common applications for this system include siRNA delivery, protein pathway mapping, and target identification.

"We are excited to receive this NIH grant for the continued development of our single-cell electroporation technology," said Cristian Ionescu-Zanetti, Ph.D., co-founder and Chief Technology Officer. "This system offers significant potential to aid research in a number of critical areas, including stem cells and siRNA delivery. This technology has the potential to improve the research activities of life science researchers worldwide."

Fluxion Biosciences develops cellular analysis tools for use in critical applications in life research and drug discovery. Fluxion has developed a proprietary microfluidic platform, CellFlux, which enables precise cellular manipulation, rapid low-volume compound addition, environmental control, and software-based data acquisition. Products include the BioFlux System for biofilm and cellular adhesion analysis, IonFlux System for cellular electrophysiology, and the CytoFlux System for stop-flow cellular imaging. These products meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, simple to use "operating system" for cellular biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.



		Fluxion Biosciences Receives NIH Grant NIH grant funds development of system critical to stem cell and siRNA research January 10, 2006, San Francisco, CA - Fluxion Biosciences, a leading developer of microfluidic systems for cellular assays in life sciences research and drug discovery, today announced that it has received a National Institutes of Health grant for the development of a single-cell electroporation system. The grant leverages the microfluidics technologies that Fluxion is developing for a wide range of cellular assays. The NIH awarded this grant to further the development of Fluxion's intracellular delivery platform. The Company has developed a bencthop workstation capable of selecting and trapping individual cells which can then be loaded with biological reagents. Common applications for this system include siRNA delivery, protein pathway mapping, and target identification. "We are excited to receive this NIH grant for the continued development of our single-cell electroporation technology," said Cristian Ionescu-Zanetti, Ph.D., co-founder and Chief Technology Officer. "This system offers significant potential to aid research in a number of critical areas, including stem cells and siRNA delivery. This technology has the potential to improve the research activities of life science researchers worldwide." About Fluxion Biosciences Fluxion Biosciences develops cellular analysis tools for use in critical applications in life research and drug discovery. Fluxion has developed a proprietary microfluidic platform, CellFlux, which enables precise cellular manipulation, rapid low-volume compound addition, environmental control, and software-based data acquisition. Products include the BioFlux System for biofilm and cellular adhesion analysis, IonFlux System for cellular electrophysiology, and the CytoFlux System for stop-flow cellular imaging. These products meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, simple to use "operating system" for cellular biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.


Home About Products Technology News Contact © 2007 Fluxion Biosciences, Inc. All rights reserved. "BioFlux", "CytoFlux" and "IonFlux" are trademarks of Fluxion Biosciences, Inc.

Fluxion Biosciences Receives NIH Grant